共 179 条
- [1] Loi S(2013)Prognostic and predictive value of tumour-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 J Clin Oncol 31 860-867
- [2] Sirtaine N(2007)Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235-244
- [3] Piette F(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434
- [4] Salgado R(2016)Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study J Clin Oncol 34 2460-2467
- [5] Viale G(2019)Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study JAMA Oncol 5 74-82
- [6] Van Eenoo F(2017)Expression of PD-L1 and prognosis in breast cancer: a meta-analysis Oncotarget. 8 31347-31354
- [7] Cleator S(2018)Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells Hum Pathol 80 170-178
- [8] Heller W(2019)PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review Breast Cancer Res Treat 174 571-584
- [9] Coombes RC(2014)PD-L1 expression in triple-negative breast cancer Cancer Immunol Res 2 361-370
- [10] Dent R(2014)Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer Breast Cancer Res Treat 146 15-24